These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15492610)

  • 1. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome.
    Durante-Mangoni E; Iardino P; Resse M; Cesaro G; Sica A; Farzati B; Ruggiero G; Adinolfi LE
    J Clin Gastroenterol; 2004; 38(10):901-5. PubMed ID: 15492610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection.
    Ruggeri C; La Masa AT; Rudi S; Squadrito G; Di Pasquale G; Maimone S; Caccamo G; Pellegrino S; Raimondo G; Magazzù G
    Dig Dis Sci; 2008 Aug; 53(8):2151-5. PubMed ID: 18231858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of coeliac disease during treatment with interferon for chronic hepatitis C.
    Cammarota G; Cuoco L; Cianci R; Pandolfi F; Gasbarrini G
    Lancet; 2000 Oct; 356(9240):1494-5. PubMed ID: 11081540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 5. Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin.
    Gombosova L; Jarcuska P; Benova B; Benicky M; Lazurova I
    Bratisl Lek Listy; 2011; 112(6):360-2. PubMed ID: 21692415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of coeliac disease and interferon treatment.
    Bourlière M; Oulés V; Perrier H; Mengotti C
    Lancet; 2001 Mar; 357(9258):803-4. PubMed ID: 11253998
    [No Abstract]   [Full Text] [Related]  

  • 7. Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study.
    Elefsiniotis IS; Fotos NV; Pantazis KD; Papadeli D; Mavrogiannis C
    Hepatogastroenterology; 2007; 54(75):2 p preceding table of contents. PubMed ID: 17591034
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C.
    Chaudhari S; Park J; Anand BS; Pimstone NR; Dieterich DT; Batash S; Bini EJ
    Dig Dis Sci; 2004 Jun; 49(6):1000-6. PubMed ID: 15309891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of interferon alpha on the induction of autoimmune thyroiditis in patients treated for chronic viral hepatitis type C.
    Krupińska J; Wawrzynowicz-Syczewska M; Urbanowicz W; Pobłocki J; Syrenicz A
    Endokrynol Pol; 2011; 62(6):517-22. PubMed ID: 22144218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease.
    Narváez I; Pérez B; del Mar Alcalde M; Jiménez C; Soria A
    Am J Gastroenterol; 2003 Oct; 98(10):2336-7. PubMed ID: 14572601
    [No Abstract]   [Full Text] [Related]  

  • 12. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
    Tahata Y; Hiramatsu N; Oze T; Morishita N; Harada N; Yamada R; Yakushijin T; Mita E; Hagiwara H; Yamada Y; Ito T; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Irishio K; Kato M; Hikita H; Sakamori R; Miyagi T; Yoshida Y; Tatsumi T; Hamasaki T; Hayashi N; Takehara T
    J Gastroenterol; 2016 Mar; 51(3):252-9. PubMed ID: 26223482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
    Perry CM; Jarvis B
    Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.
    Tahan V; Ozseker F; Guneylioglu D; Baran A; Ozaras R; Mert A; Ucisik AC; Cagatay T; Yilmazbayhan D; Senturk H
    Dig Dis Sci; 2003 Jan; 48(1):169-73. PubMed ID: 12645805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Pellicelli A; Grisorio B; Barbarini G
    J Hepatol; 2000 Sep; 33(3):448-55. PubMed ID: 11020001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
    Hoffmann RM; Jung MC; Motz R; Gössl C; Emslander HP; Zachoval R; Pape GR
    J Hepatol; 1998 Jun; 28(6):1058-63. PubMed ID: 9672184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic hepatitis C with early complication of Grave's disease during the treatment of pegylated interferon alpha-2a].
    Maede Y; Morishita K; Iwamura K; Takayama Y; Tsukada Y; Kishino M; Shimizu T; Matsushima S; Komatsu T; Kasagi Y
    Nihon Naika Gakkai Zasshi; 2005 Dec; 94(12):2600-2. PubMed ID: 16419601
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.
    Ascione A; De Luca M; Di Costanzo GG; Picciotto FP; Lanza AG; Canestrini C; Morisco F; Tuccillo C; Caporaso N
    Curr Pharm Des; 2002; 8(11):977-80. PubMed ID: 11945144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Oshita M; Mita E; Ito T; Inui Y; Inada M; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
    J Viral Hepat; 2015 Mar; 22(3):254-62. PubMed ID: 25081140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.